Accolade Inc. currently has liabilities amounting to 316.8 million, with a Debt to Equity (D/E) ratio of 0.63. This ratio is approximately average when compared to similar companies. On a performance scale of 0 to 100, Accolade Inc. scores an 11. The company has a Beta (market volatility) of 3.57, indicating a somewhat significant risk relative to the market. If the market rises, the company is expected to outperform it. However, if the market experiences negative returns, Accolade Inc. is likely to underperform.
We have identified twenty-one technical indicators for Accolade Inc., which can be used to evaluate the company's performance. Please consider using Accolade Inc.'s mean deviation, standard deviation, and Treynor ratio, as well as the relationship between the downside deviation and information ratio, to make a quick decision on whether Accolade Inc.'s price patterns will revert.
Main Ideas
AccoladeInc, a key player in the Health Information Services industry, presents an enticing buying opportunity as share prices take a slight dip today. With a Z Score of
1.52, the company stands in a good
financial health. Despite reporting a significant loss of
$459.6M in net income, AccoladeInc has demonstrated a robust total revenue of
$363.1M. Furthermore, the company's book value per share is estimated at 5.75X, offering a potentially attractive valuation for investors. Considering the current market volatility, investors might want to take advantage of the lower share price to buy into AccoladeInc's potential future growth.
We determine the current worth of AccoladeInc using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AccoladeInc based exclusively on its
fundamental and basic
technical indicators. By analyzing AccoladeInc's
financials, quarterly and monthly indicators, and related drivers such as
dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of
AccoladeInc's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of AccoladeInc. We calculate exposure to AccoladeInc's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to AccoladeInc's related companies.
AccoladeInc Investment Alerts
AccoladeInc investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring AccoladeInc performance across your portfolios.Please check all
investment alerts for AccoladeInc
AccoladeInc Valuation Ratios as Compared to Competition
Our valuation model uses many indicators to compare AccoladeInc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AccoladeInc competition to find
correlations between indicators driving the intrinsic value of AccoladeInc.
AccoladeInc Gross Profit
AccoladeInc Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing AccoladeInc previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show AccoladeInc Gross Profit growth over the last 10 years. Please check AccoladeInc's
gross profit and other
fundamental indicators for more details.
Is AccoladeInc valued correctly by the market?
The latest price surge of AccoladeInc could raise concerns from shareholders as the firm is trading at a share price of
11.14 on very low momentum in volume. The company executives may have good odds in positioning the firm resources to exploit
market volatility in
February. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.92. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from AccoladeInc partners.
Margins Breakdown
AccoladeInc profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or AccoladeInc itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of AccoladeInc profit margins.
| EBITDA Margin | (1.06) |
| Gross Margin | 0.51 |
| Profit Margin | (1.17) |
AccoladeInc Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. Further, AccoladeInc Average Equity is rather stable at the moment.
AccoladeInc Earnings Before Interest Taxes and Depreciation Amortization USD is decreasing over the last 8 years. Further, AccoladeInc Average Equity is rather stable at the moment. As Warren Buffet once said, "Be fearful when others are greedy and greedy when others are fearful." Today, AccoladeInc's shares are presenting a potential buying opportunity as prices dip. Despite a net income loss of $459.6M, the company's strong current ratio of 3.33X and working capital of $246.53M indicate a healthy short-term financial position. Furthermore, the company's book value stands at 5.752, while the price to book ratio is 1.94X, suggesting that the stock may be undervalued. However, investors should be aware of the company's high probability of bankruptcy at 68.18%. Despite this, with 84.95% of shares owned by institutions, it's clear that the market sees potential in this healthcare information services provider. As always, investors are advised to do their own due diligence before making any investment decisions. .
AccoladeInc is projected to stay under $11.36 in February
Accolade Inc., a prominent provider of personalized health and benefits solutions, is expected to maintain a trading price below $11.36 in February. This forecast is backed by the recent drop in the coefficient of variation to 1787.95, suggesting a possible decrease in volatility. Investors are advised to closely monitor this stock, as the diminished volatility could offer a more stable investment opportunity in the near term. However, as always, it's essential to take into account other market factors and personal investment objectives before making any trading decisions. Accolade Inc. displays an above-average semi-deviation for the current time horizon. We urge investors to examine Accolade Inc. individually to ensure that intended
market timing strategies and available technical indicators are in line with their projections about Accolade Inc.'s future systematic risk. Understanding varying
market volatility trends often assists investors in timing the market. The correct use of volatility indicators allows traders to measure Accolade Inc.'s stock risk against market volatility during both bullish and bearish trends.
The elevated level of volatility that accompanies bear markets can directly affect Accolade Inc.'s stock price, adding stress to investors as they witness the value of their shares plummet. This typically compels investors to rebalance their portfolios by purchasing different stocks as prices drop. In light of today's dip in AccoladeInc's stock, it's crucial to consider the company's financial outlook. Analysts have given an overall consensus of a 'Buy' rating, with
9 strong buys,
2 buys, and
5 holds. The estimated EPS for the next fiscal year, ending in February, is -1.31. However, the naive expected forecast value is 10.37, indicating potential for growth. The possible upside price is 14.29, with a downside risk of 6.45. The valuation real value stands at 11.63, slightly above the market value of 11.14. The analyst target price estimated value is 14.5, with the highest estimated target price reaching
19.001. Given these data points, AccoladeInc presents a promising investment opportunity despite the current dip. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of AccoladeInc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
